APLS Apellis Pharmaceuticals, Inc. Stock Quote

APLS [NASD]

Index	-	P/E	-	EPS (ttm)	-8.02	Insider Own	2.70%	Shs Outstand	98.07M	Perf Week	14.37%
Market Cap	4.70B	Forward P/E	-	EPS next Y	-4.53	Insider Trans	-2.43%	Shs Float	88.42M	Perf Month	-7.92%
Income	-701.60M	PEG	-	EPS next Q	-1.28	Inst Own	86.30%	Short Float	9.97%	Perf Quarter	4.10%
Sales	80.90M	P/S	58.06	EPS this Y	-92.70%	Inst Trans	12.15%	Short Ratio	7.14	Perf Half Y	1.12%
Book/sh	4.71	P/B	9.43	EPS next Y	18.30%	ROA	-86.30%	Target Price	72.36	Perf Year	-5.89%
Cash/sh	9.13	P/C	4.87	EPS next 5Y	33.30%	ROE	-607.40%	52W Range	27.50 - 73.00	Perf YTD	-6.05%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-86.10%	52W High	-39.15%	Beta	1.59
Dividend %	-	Quick Ratio	8.60	Sales past 5Y	-	Gross Margin	92.00%	52W Low	61.53%	ATR	3.28
Employees	476	Current Ratio	8.80	Sales Q/Q	-75.90%	Oper. Margin	-	RSI (14)	50.80	Volatility	7.94% 8.23%
Optionable	Yes	Debt/Eq	1.18	EPS Q/Q	38.90%	Profit Margin	-	Rel Volume	0.50	Prev Close	44.81
Shortable	Yes	LT Debt/Eq	1.17	Earnings	May 04 AMC	Payout	-	Avg Volume	1.23M	Price	44.42
Recom	1.90	SMA20	4.40%	SMA50	-6.79%	SMA200	0.11%	Volume	617,682	Change	-0.87%

Apr-14-22

Downgrade

ROTH Capital

Neutral → Sell

$40

Dec-08-21

Initiated

Wells Fargo

Overweight

$84

Nov-29-21

Downgrade

ROTH Capital

Buy → Neutral

$46 → $40

Sep-10-21

Reiterated

Oppenheimer

Outperform

$80 → $65

Sep-10-21

Reiterated

Needham

Buy

$85 → $70

Sep-10-21

Reiterated

Credit Suisse

Neutral

$50 → $38

Sep-10-21

Reiterated

BMO Capital Markets

Outperform

$89 → $69

Sep-10-21

Downgrade

Wedbush

Outperform → Neutral

$71 → $39

Aug-19-21

Upgrade

Wedbush

Neutral → Outperform

Aug-19-21

Initiated

Jefferies

Buy

$74

May-21-21

Initiated

UBS

Buy

$82

Apr-16-21

Initiated

Goldman

Buy

$130

Nov-19-20

Initiated

Needham

Buy

$59

Sep-01-20

Initiated

Stifel

Buy

$40

Jul-20-20

Initiated

ROTH Capital

Buy

$50

Jun-17-20

Initiated

BTIG Research

Neutral

Apr-01-20

Initiated

Raymond James

Strong Buy

$86

Mar-31-20

Initiated

BMO Capital Markets

Outperform

$54

Mar-11-20

Upgrade

Wedbush

Underperform → Neutral

$29

Jan-07-20

Initiated

SVB Leerink

Mkt Perform

$30

May-12-22 11:05AM	Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress GlobeNewswire
May-06-22 04:23PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -8.75%
09:55AM	Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top Zacks
May-05-22 04:05PM	Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference GlobeNewswire
10:04AM	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Analysts Just Trimmed Their Revenue Forecasts By 16% Simply Wall St.
May-04-22 06:15PM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results GlobeNewswire
May-03-22 07:00AM	Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company GlobeNewswire
May-02-22 03:30PM	Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting GlobeNewswire
Apr-26-22 07:00AM	Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results GlobeNewswire -5.99%
Apr-22-22 01:19PM	Apellis (APLS) Thrives on Empaveli, Stiff Competition a Woe Zacks -5.17%
Apr-21-22 07:00AM	Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA) GlobeNewswire
Apr-11-22 11:46AM	12 Best US Stocks to Buy Now Insider Monkey
Apr-04-22 02:53PM	Apellis Pharmaceuticals Stock Shows Rising Relative Strength Investor's Business Daily +6.11%
07:00AM	Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-30-22 11:30AM	Why Is Apellis Pharmaceuticals, Inc. (APLS) Up 8.9% Since Last Earnings Report? Zacks
Mar-29-22 01:03PM	Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development Zacks
Mar-28-22 04:01PM	Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Mar-24-22 07:00AM	Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -6.24%
Mar-23-22 04:03PM	Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-16-22 04:07PM	Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing Investor's Business Daily +12.96%
11:41AM	Apellis' Pegcetacoplan Showed Continuous, Meaningful Effects At Month 18 In Geographic Atrophy Studies Benzinga
08:37AM	Apellis shares jump 6% after the company announces new data for its geographic atrophy drug MarketWatch
07:00AM	Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA) GlobeNewswire
Mar-02-22 07:00AM	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Mar-01-22 09:34AM	Apellis (APLS) Q4 Loss Widens, Revenues Surpass Estimates Zacks +5.20%
Feb-28-22 05:45PM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Feb-24-22 07:55AM	5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates Zacks
Feb-23-22 11:11AM	Novavax (NVAX) to Report Q4 Earnings: What's in the Cards? Zacks
08:43AM	Why Apellis (APLS) Might Surprise This Earnings Season Zacks
Feb-22-22 07:00AM	Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Feb-21-22 11:26AM	Avid (CDMO) to Report Q3 Earnings: What's in the Cards? Zacks
Feb-17-22 03:03PM	Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Feb-10-22 04:45AM	Investors bid Apellis Pharmaceuticals (NASDAQ:APLS) up US$777m despite increasing losses YoY, taking three-year CAGR to 51% Simply Wall St.
Feb-07-22 11:36AM	Did Hedge Funds Get Apellis Pharmaceuticals, Inc. (APLS) Right? Insider Monkey +7.45%
Feb-02-22 01:38PM	HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ... GuruFocus.com
Jan-24-22 01:38PM	Ipswich Investment Management Co., Inc. Buys GXO Logistics Inc, Stag Industrial Inc, Moderna ... GuruFocus.com +9.36%
Jan-19-22 01:38PM	Sippican Capital Advisors Buys Coterra Energy Inc, DaVita Inc, Physicians Realty Trust, Sells ... GuruFocus.com
Jan-06-22 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-03-22 12:05PM	Apellis (APLS) Up More Than 40% in Past 3 Months: Here's Why Zacks
07:00AM	Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-23-21 05:38AM	MainStay VP Wellington Small Cap Portfolio Buys iShares Russell 2000 Growth ETF, United Natural ... GuruFocus.com
Dec-16-21 09:38AM	Apellis (APLS), Sobi Get EU Nod for Rare Blood Disorder Drug Zacks
Dec-15-21 10:14AM	Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder Benzinga
07:00AM	Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH GlobeNewswire
Dec-13-21 11:45AM	Apellis and Sobi Report Empaveli (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population GlobeNewswire
Dec-10-21 08:10AM	Do Hedge Funds Love Apellis Pharmaceuticals, Inc. (APLS)? Insider Monkey
Dec-09-21 09:31AM	Wells Fargo Bullish on These 2 Stocks for 90% Upside (Or More) TipRanks
Nov-29-21 07:00AM	Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire
Nov-18-21 04:01PM	Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Nov-16-21 07:00AM	Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire +11.95%
Nov-15-21 04:01PM	Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Nov-12-21 07:00AM	Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback GlobeNewswire +11.62%
Nov-10-21 07:00AM	Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting GlobeNewswire
Nov-09-21 10:45AM	Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates Zacks +10.83%
Nov-08-21 05:15PM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results GlobeNewswire
Nov-04-21 09:17AM	Apellis to Present New Data Reinforcing EMPAVELI (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting GlobeNewswire
Nov-03-21 07:00AM	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Nov-01-21 07:00AM	Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results GlobeNewswire +5.73%
Oct-25-21 03:01PM	Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-21-21 02:21AM	Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised) Zacks
Oct-18-21 10:20AM	Is Apellis Pharmaceuticals, Inc. (APLS) Going to Burn These Hedge Funds? Insider Monkey
10:17AM	Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug Zacks
Oct-15-21 07:17AM	Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH GlobeNewswire
Oct-06-21 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-30-21 11:49AM	Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting GlobeNewswire
Sep-22-21 12:02PM	4 Midsize Biotech Stocks That Have Breakout Potential Barrons.com
Sep-20-21 07:00AM	Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-13-21 11:02AM	Apellis (APLS) Down on Mixed Data From Studies on GA Candidate Zacks -7.76%
Sep-10-21 04:11PM	Apellis Loses A Third Of Its Value; Are Its Mixed Results Enough To Win FDA OK? Investor's Business Daily -37.19%
03:07PM	Mid-Afternoon Market Update: Dow Slides Over 100 Points; Echo Global Logistics Shares Spike Higher Benzinga
12:49PM	Why Apellis Pharmaceutical Shares Are Plunging Today Benzinga
12:31PM	Mid-Day Market Update: Crude Oil Rises Over 2%; Apellis Pharmaceuticals Shares Plunge Benzinga
11:39AM	Here's Why Iveric Bio Stock Is Rocketing Higher Today Motley Fool
10:58AM	ISEE Stock: Why Rival Eye Drug Developers Disappointment Is a Boon to IVERIC bio InvestorPlace
10:52AM	Here's Why Apellis Pharmaceuticals Is Getting Hammered Today Motley Fool
10:40AM	Why IVERIC Bio Shares Are Soaring Today Benzinga
10:21AM	Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views Benzinga
08:00AM	Apellis Pharmaceuticals stock plunges after disappointing result from GA treatment studies MarketWatch
06:35AM	Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line Benzinga
Sep-09-21 04:05PM	Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022 GlobeNewswire
Sep-08-21 11:30AM	Apellis Pharmaceuticals, Inc. (APLS) Down 6.8% Since Last Earnings Report: Can It Rebound? Zacks
Sep-07-21 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -12.88%
Sep-03-21 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller / Chief Accounting Officer GlobeNewswire
Aug-11-21 08:36AM	Is the Options Market Predicting a Spike in Apellis (APLS) Stock? Zacks
Aug-10-21 03:36PM	Apellis' (APLS) Q2 Earnings & Revenues Fall Shy of Estimates Zacks
Aug-09-21 05:25PM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:01PM	Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results GlobeNewswire
Aug-06-21 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-02-21 01:51AM	Did Business Growth Power Apellis Pharmaceuticals' (NASDAQ:APLS) Share Price Gain of 277%? Simply Wall St.
Jul-29-21 08:33AM	Why Apellis (APLS) Might Surprise This Earnings Season Zacks
07:00AM	Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results GlobeNewswire
Jul-26-21 07:00AM	Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock GlobeNewswire
Jul-07-21 10:06PM	Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock GlobeNewswire
04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-06-21 07:42AM	Apellis Pipeline Creating Attractive Entry Point, Analyst Says TipRanks
Jul-02-21 09:19AM	Apellis (APLS) Up on Tie-up With Beam for Novel Therapies Zacks
Jun-30-21 04:15PM	Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases GlobeNewswire

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Machiels Alec	Director	May 16	Option Exercise	2.67	1,250	3,338	265,024	May 17 05:26 PM
Machiels Alec	Director	May 16	Sale	39.18	1,250	48,975	263,774	May 17 05:26 PM
Grossi Federico	CHIEF MEDICAL OFFICER	May 02	Sale	43.56	2,500	108,900	112,061	May 03 07:56 PM
Deschatelets Pascal	Chief Scientific Officer	Apr 29	Option Exercise	2.67	4,000	10,680	895,775	May 02 08:05 PM
Deschatelets Pascal	Chief Scientific Officer	Apr 29	Sale	44.43	4,000	177,720	891,775	May 02 08:05 PM
Watson David O.	General Counsel	Apr 25	Sale	50.00	5,000	250,000	125,569	Apr 27 04:39 PM
Dunlop A. Sinclair	Director	Apr 22	Option Exercise	14.00	20,000	280,000	91,124	Apr 25 09:35 PM
DeLong Mark Jeffrey	Senior Vice President	Apr 20	Option Exercise	15.52	7,000	108,640	35,481	Apr 22 05:35 PM
DeLong Mark Jeffrey	Senior Vice President	Apr 20	Sale	52.53	7,000	367,710	28,481	Apr 22 05:35 PM
Machiels Alec	Director	Apr 14	Option Exercise	2.67	1,250	3,338	265,024	Apr 18 07:42 PM
Machiels Alec	Director	Apr 14	Sale	50.90	1,250	63,625	263,774	Apr 18 07:42 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Apr 05	Option Exercise	13.85	609	8,435	52,842	Apr 06 04:10 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Apr 05	Sale	60.09	609	36,593	52,233	Apr 06 04:10 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Apr 04	Option Exercise	13.85	3,504	48,530	55,737	Apr 05 04:08 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Apr 04	Sale	56.96	3,504	199,589	52,233	Apr 05 04:08 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Apr 01	Option Exercise	13.85	11,496	159,220	63,729	Apr 04 05:03 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Apr 01	Sale	55.05	11,496	632,855	52,233	Apr 04 05:03 PM
Machiels Alec	Director	Mar 15	Option Exercise	2.67	1,250	3,338	260,794	Mar 17 08:59 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Mar 15	Option Exercise	4.31	7,000	30,170	116,811	Mar 17 06:19 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Mar 15	Sale	39.57	375	14,839	116,436	Mar 17 06:19 PM
Machiels Alec	Director	Mar 15	Sale	39.57	1,250	49,462	259,544	Mar 17 08:59 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Mar 01	Sale	43.53	375	16,324	109,811	Mar 02 06:15 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Feb 23	Option Exercise	4.31	4,100	17,671	110,186	Feb 24 04:33 PM
Machiels Alec	Director	Feb 15	Option Exercise	2.67	1,250	3,338	675,024	Feb 16 04:29 PM
Machiels Alec	Director	Feb 15	Sale	45.43	1,250	56,788	673,774	Feb 16 04:29 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Feb 15	Sale	45.43	375	17,036	106,086	Feb 16 04:29 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Feb 14	Option Exercise	4.31	3,600	15,516	106,461	Feb 15 04:59 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Feb 14	Option Exercise	26.73	720	19,246	52,233	Feb 15 04:58 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Feb 11	Sale	46.80	1,666	77,969	51,513	Feb 14 06:20 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Feb 08	Option Exercise	13.85	10,000	138,500	63,857	Feb 10 08:32 AM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Feb 08	Sale	45.00	10,000	450,000	53,857	Feb 10 08:32 AM
Grossi Federico	CHIEF MEDICAL OFFICER	Feb 01	Sale	40.58	375	15,218	103,566	Feb 02 04:50 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Jan 31	Sale	38.47	1,233	47,434	53,857	Feb 01 05:58 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Jan 21	Option Exercise	26.73	3,021	80,751	29,681	Jan 24 05:26 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Jan 14	Option Exercise	4.31	3,400	14,654	78,915	Jan 19 08:03 PM
Machiels Alec	Director	Jan 14	Option Exercise	2.67	1,250	3,338	675,024	Jan 19 08:15 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Jan 14	Sale	40.56	375	15,210	78,540	Jan 19 08:03 PM
Machiels Alec	Director	Jan 14	Sale	40.56	1,250	50,700	673,774	Jan 19 08:15 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Jan 12	Option Exercise	3.92	5,161	20,230	75,515	Jan 14 04:57 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Jan 03	Sale	47.31	375	17,741	70,354	Jan 04 04:07 PM
Watson David O.	General Counsel	Dec 27	Sale	48.50	1,200	58,200	107,534	Dec 28 05:38 PM
Watson David O.	General Counsel	Dec 22	Option Exercise	14.40	20,112	289,674	114,131	Dec 23 04:58 PM
Watson David O.	General Counsel	Dec 22	Sale	47.81	10,571	505,373	104,019	Dec 23 04:58 PM
Machiels Alec	Director	Dec 15	Option Exercise	2.67	3,000	8,010	672,544	Dec 17 05:09 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Dec 15	Sale	42.88	375	16,080	70,729	Dec 17 05:10 PM
Machiels Alec	Director	Dec 15	Sale	42.88	3,000	128,640	669,544	Dec 17 05:09 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Dec 08	Option Exercise	3.76	7,000	26,320	71,104	Dec 09 04:57 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Dec 01	Sale	42.40	375	15,900	64,104	Dec 03 04:00 PM
Morningside Venture Investment	10% Owner	Nov 18	Buy	40.00	250,000	10,000,000	12,806,342	Nov 18 04:16 PM
Machiels Alec	Director	Nov 15	Option Exercise	2.67	3,000	8,010	672,544	Nov 17 05:01 PM
Machiels Alec	Director	Nov 15	Sale	43.50	3,000	130,500	669,544	Nov 17 05:01 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Nov 15	Sale	43.50	625	27,188	64,479	Nov 17 05:02 PM
Machiels Alec	Director	Nov 04	Option Exercise	2.67	3,000	8,010	672,544	Nov 17 05:01 PM
Machiels Alec	Director	Nov 04	Sale	35.00	3,000	105,000	669,544	Nov 17 05:01 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Nov 01	Sale	30.70	625	19,188	64,805	Nov 02 04:01 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Oct 14	Sale	34.57	750	25,928	65,430	Oct 15 04:02 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Oct 01	Sale	33.26	750	24,945	66,180	Oct 05 04:16 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Sep 28	Option Exercise	3.76	4,000	15,040	66,930	Sep 29 09:48 PM
Dunlop A. Sinclair	Director	Sep 10	Option Exercise	14.00	6,894	96,516	66,894	Sep 13 04:10 PM
Watson David O.	General Counsel	Sep 10	Option Exercise	4.31	954	4,112	99,193	Sep 13 04:08 PM
Machiels Alec	Director	Aug 16	Option Exercise	2.67	2,500	6,675	672,044	Aug 17 04:42 PM
Machiels Alec	Director	Aug 16	Sale	56.95	2,500	142,375	669,544	Aug 17 04:42 PM
Perry Nicole D	Vice President - Accounting	Aug 02	Option Exercise	3.76	1,000	3,760	5,847	Aug 03 04:23 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Aug 02	Sale	63.99	250	15,998	62,930	Aug 03 04:26 PM
Perry Nicole D	Vice President - Accounting	Aug 02	Sale	63.99	1,000	63,990	4,847	Aug 03 04:23 PM
DeLong Mark Jeffrey	Senior Vice President	Jul 21	Option Exercise	15.52	1,000	15,520	10,490	Jul 22 04:24 PM
Francois Cedric	Chief Executive Officer	Jul 21	Option Exercise	4.31	14,410	62,107	1,234,243	Jul 22 04:04 PM
DeLong Mark Jeffrey	Senior Vice President	Jul 21	Sale	65.00	1,000	65,000	9,490	Jul 22 04:24 PM
DeLong Mark Jeffrey	Senior Vice President	Jul 15	Option Exercise	15.52	1,000	15,520	10,490	Jul 16 06:40 PM
Machiels Alec	Director	Jul 15	Option Exercise	2.67	2,500	6,675	672,044	Jul 16 06:38 PM
DeLong Mark Jeffrey	Senior Vice President	Jul 15	Sale	62.30	1,000	62,300	9,490	Jul 16 06:40 PM
Machiels Alec	Director	Jul 15	Sale	62.30	2,500	155,750	669,544	Jul 16 06:38 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Jul 14	Sale	64.68	500	32,340	63,180	Jul 15 04:56 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Jul 08	Sale	65.68	250	16,420	63,680	Jul 09 03:59 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Jun 28	Option Exercise	3.76	9,000	33,840	63,930	Jun 29 04:58 PM
Deschatelets Pascal	Chief Scientific Officer	Jun 24	Option Exercise	2.67	6,250	16,688	875,837	Jun 25 09:48 PM
Deschatelets Pascal	Chief Scientific Officer	Jun 24	Sale	65.61	6,250	410,062	869,587	Jun 25 09:48 PM
Watson David O.	General Counsel	Jun 21	Option Exercise	4.31	489	2,108	98,239	Jun 22 04:02 PM
Machiels Alec	Director	Jun 15	Option Exercise	2.67	2,500	6,675	672,044	Jun 16 04:33 PM
DeLong Mark Jeffrey	Senior Vice President	Jun 15	Option Exercise	15.52	4,000	62,080	13,490	Jun 16 04:32 PM
Machiels Alec	Director	Jun 15	Sale	64.83	2,500	162,075	669,544	Jun 16 04:33 PM
DeLong Mark Jeffrey	Senior Vice President	Jun 15	Sale	64.96	4,000	259,830	9,490	Jun 16 04:32 PM
Grossi Federico	CHIEF MEDICAL OFFICER	Jun 14	Sale	61.84	500	30,920	54,930	Jun 15 04:03 PM
Perry Nicole D	Vice President - Accounting	Jun 11	Option Exercise	3.20	1,000	3,200	5,847	Jun 15 04:04 PM
Perry Nicole D	Vice President - Accounting	Jun 11	Sale	61.55	1,000	61,555	4,847	Jun 15 04:04 PM
SCHEIBLER LUKAS	CHIEF INNOVATION OFFICER	Jun 10	Sale	60.00	3,417	205,020	26,651	Jun 11 04:07 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jun 08	Option Exercise	10.03	39,880	399,996	74,141	Jun 09 04:06 PM
Perry Nicole D	Vice President - Accounting	Jun 01	Option Exercise	3.76	1,000	3,760	5,847	Jun 02 04:15 PM
Perry Nicole D	Vice President - Accounting	Jun 01	Sale	56.40	1,000	56,400	4,847	Jun 02 04:15 PM
Watson David O.	General Counsel	May 28	Option Exercise	4.31	489	2,108	97,750	Jun 01 04:53 PM
Deschatelets Pascal	Chief Scientific Officer	May 24	Option Exercise	2.67	6,250	16,688	875,837	May 25 04:01 PM
Deschatelets Pascal	Chief Scientific Officer	May 24	Sale	47.40	6,250	296,250	869,587	May 25 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience